Stem Cell Therapy in Spinal Cord Injury

Open Label Study of Autologous Bone Marrow Mononuclear Cells in Spinal Cord Injury

The purpose of this study is to study the effect of stem cell therapy on common symptoms in patients with spinal cord injury.

Autologous bone marrow mononuclear cells are administered intrathecally by a standard procedure followed by vigorous rehabilitation therapy.

Inclusion Criteria:

• Diagnosed cases of any type of spinal cord injury
• age above 12 months.

Exclusion Criteria:

• presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus
• malignancies
• bleeding tendencies
• pneumonia
• renal failure
• severe liver dysfunction
• severe anemia [Hemoglobin < 8]
• any bone marrow disorder
• space occupying lesion in brain
• other acute medical conditions such as respiratory infection and pyrexia.